Total dose and frequency of administration critically affect success of nasal mucosal tolerance induction

Hui-Rong Jiang, Neil Taylor, Linda Duncan, Andrew D Dick, John V Forrester

Abstract

Aims—Nasal tolerance induction with autoantigens can effectively protect against a variety of experimental models of autoimmune disease. The aims of this study were to characterise the dosage and kinetics of inhibition of experimental autoimmune uveoretinitis (EAU) via intranasal administration of the uvoretinogenic antigen interphotoreceptor retinal binding protein (IRBP) in the murine model of IRBP induced EAU.

Methods—B10RIII mice were tolerised by intranasal administration of IRBP either with a long term multiple low dose or a short term/high dose regimen before subcutaneous immunisation with IRBP in complete Freund’s adjuvant (CFA). On day 15 post-immunisation, mice were killed and eyes were removed for histological examination and quantification of inflammatory cell infiltration and degree of target organ (rod outer segment, ROS) destruction.

Results—Nasal administration of multiple low doses of IRBP (1 µg or 3 µg IRBP per mouse per day for 10 days) significantly protected mice from IRBP induced EAU. Short term/high dose regimens were only effective when given either as a single or, at most, as two consecutive doses (40 µg per dose). Multiple doses in the range of 45–120 µg over 3 days afforded no protection.

Conclusions—These results indicate that both dose and frequency of intranasal antigen administration are pivotal to tolerance induction and subsequent suppression of T cell mediated autoimmune disease.

Experimental autoimmune uveitis (EAU) is a T cell mediated disease that specifically targets the neural retina. Although EAU can be induced by a variety of retinal antigens in many different animal strains, EAU in the mouse more closely resembles the pathology of a different animal strains, EAU in the mouse more closely resembles the pathology of a different animal strains, including both peptide a and CD8+ T cells, all of which are dependent upon the dose and route of antigen delivery. Recent data have in part shifted emphasis towards the central role of CD4+ T cells and IL-2, including both peptide affinity for MHC class II binding and as well as inherent hierarchical ability of T cell epitopes to induce tolerance. With respect to CD4+ T cells, mucosal administration of autoantigen results in early activation and subsequent apoptosis of T cell populations. Studies of transgenic (Tg) mice have shown that the success of tolerance therapy is dependent upon the duration of therapy that in turn is dependent upon the precursor frequency of antigen specific T cells. In both Tg OVA and AC1-9TCR Tg mice following intranasal antigen delivery early activation followed by a transient and incomplete deletion of T cells was observed. Residual T cells remained unresponsive, although in the EAE model, they produced IL-10. Such results are comparable with our previous data in EAU in rat showing that, following intranasal retinal antigen delivery, lymph node cells were activated (IFN-γ spurt) and on further antigen challenge increased levels of apoptosis were noted within the draining lymph node. Although regulatory cells were generated, tolerance could only be transferred via spleen cells. Moreover, the cells that did infiltrate the retina in tolerised animals produced IL-10.
Although the precise mechanisms of nasal tolerance induction remain undefined the specific draining lymph nodes, which directly drain the nasal or oral mucosa, do constitute a unique microenvironment, without which tolerance induction is not possible.30

Mucosal tolerance is more effective following nasal administration compared with oral administration of antigens at the same dose.31 Following our previous observations of nasal tolerance with serial doses of intranasal retinal antigens in suppressing EAU in Lewis rat,32 the aims of the present work were to better characterise the dosage and kinetics of inhibition of IRBP induced EAU via intranasal IRBP administration in a murine model.33

Materials and methods

Antigen

IRBP was prepared as previously described.34 Briefly, interphotoreceptor matrix was loaded onto a concanavalin-A (Con-A) sepharose affinity chromatography column (Pharmacia, Sweden) and crude IRBP eluted using TRIS-HCl/0.15 mM NaCl/1 mM CaCl2/1 mM MnCl2/0.2 mM methyl-B-mannopyranoside, pH 7.5 (Sigma, UK). Further purification was achieved using a sepharose high performance chromatograph (Pharmacia) and mannose agarose affinity column (Sigma, UK) to remove contaminating ConA. The purified IRBP was dialysed against PBS and then the concentration of the IRBP was tested by Coomassie protein assay reagent (Pierce, UK). The purified IRBP produced a single band on SDS-PAGE and was aliquoted and stored at −20°C before use.

Animals

Inbred male B10RIII mice 8–12 weeks of age were obtained from the biological service unit at the medical school, University of Aberdeen. The procedures adopted conformed to the regulations of the Animal Licence Act (UK), and to the ARVO statement for the use of animals in ophthalmic and vision research.

Induction of nasal tolerance

(A) Multiple 10 day (2 week ×5) low dose tolerance induction regimen

Three groups of animals (with 10 mice in each group) were administered intranasally to a total dose of 30 µg or 10 µg IRBP over 10 daily applications within 2 weeks (day −21 to −10). Controls were simultaneously treated with phosphate buffered saline (PBS). All mice were immunised on day 0 with IRBP in CFA, and with additional pertussis toxin adjuvant (PTX) (see EAU induction).

(B) 1, 2, or 3 dose tolerance induction (varying total antigen dose)

Four groups of mice (eight mice in each group) were administered intranasally to a total of 120 µg IRBP per mouse over 3 days (from day −12 to −10), a total of 80 µg IRBP per mouse over 2 days (day −11 and day −10), or a single dose of 40 µg IRBP (day −10). Controls received PBS and, following intranasal administration, all animals were challenged with IRBP in CFA and PTX 9 days later.

(C) 1, 2, or 3 dose tolerance induction (total antigen dose constant)

Five groups of mice (six mice in each group) were administered intranasally to a total of 45 µg IRBP per mouse over 3 days (from day −12 to −10), a total of 45 µg IRBP per mouse over 2 days (from day −11 to day −10), a single dose of 45 µg IRBP per mouse, or PBS. All mice were then immunised with IRBP in CFA, and with additional PTX.

Statistical analysis

Statistical analysis was performed using SPSS software. Analysis of the EAU grades (non-parametric) was performed by Mann-Whitney. A p value of <0.05 was considered statistically significant.

Results

Multiple low doses of IRBP intranasally protect mice against EAU

To investigate the effect of multiple low doses of IRBP on the development of IRBP induced B10RIII mice EAU, animals were treated with IRBP intranasally 10 days before immunisation at doses of 1 µg and 3 µg as described in...
the antigen and PBS tolerised groups are detailed.

Incidence (diseased/total mice), EAU histological grade mean and SD, and p value between the antigen and PBS tolerised groups are detailed.

![Figure 1](image1.png)

**Figure 1** Multiple low dose intranasal administered IRBP suppresses IRBP induced EAU. EAU was markedly suppressed in tolerising a total of 10 µg or 30 µg IRBP administered intranasally over 10 days compared with the PBS pretreated mice. Incidence (diseased/total mice), EAU histological grade mean (SD), and p value between the antigen and PBS tolerised groups are detailed.

Incidence 10/10 4/10 7/10
Grade mean 9.4 2.4 2.9
SD 2.0 4.0 3.2
p Value 0.001 0.001

the Methods section. Control mice were given 10 doses of PBS on the same days. Nine days after completion of administration of antigen intranasally, all mice were challenged by immunising with a uveitogenic dose of IRBP. Ten animals in each group were tested. Figure 1 shows the incidence and mean severity grade (SD) of EAU. Eyes collected and processed on day 15 post-immunisation showed that mice that had received the lowest total dose of 10 µg IRBP over 10 days displayed the greatest suppression of EAU (with 4/10 incidence and severity grade of 2.4) and protection against destruction compared with the control group (with 10/10 incidence and grade of 9.4) (p = 0.001). Significant suppression of EAU was also observed in animals receiving a total dose of 30 µg IRBP over 10 days (with 7/10 incidence and EAU grade at 2.9). Thus, both the incidence and severity of EAU were reduced markedly using this regime especially at the low dose of 1 µg/day for 10 days.

![Figure 2](image2.png)

**Figure 2** A single high dose of intranasal IRBP is effective in protecting mice from EAU. EAU was suppressed significantly by a single intranasal dose of 40 µg or two doses of 80 µg, but not by a total of 120 µg IRBP administered intranasally over 3 days. Incidence (diseased/total mice), EAU histological grade mean and SD, and p value between the antigen and PBS tolerised groups are detailed.

Incidence 7/8 2/8 3/8 6/8
Grade mean 5.2 1.0 1.3 4.7
SD 3.1 1.8 1.8 3.3
p Value 0.008 0.011 0.833

One and two, but not three “high” consecutive doses of antigen intranasally are effective in preventing EAU.

Both in the Lewis rat and, as this study shows, in murine EAU, multiple low doses of antigen by nasal administration are very effective in protecting animals from developing EAU and the effect is dose dependent. We therefore wished to investigate whether a single large dose of antigen could have the same effect as multiple small doses. In this part of the study eight animals in each group were studied. As shown in Figure 2, a single dose of 40 µg of IRBP administered 10 days before challenge significantly inhibited disease severity (incidence 2/8, grade 1.0). Two high doses (total 80 µg IRBP) on successive days were also very effective in generating suppression of EAU (incidence 3/8, EAU grade 1.3). Increasing the dose to a total of 120 µg IRBP over 3 consecutive days failed to induce tolerance and disease suppression (incidence 6/8, grade 4.7). In this group, all mice developed severe EAU with marked target organ damage with no significant difference compared with the control group, which had an incidence of 7/8 and EAU grade at 5.2.

Failure to prevent EAU with the three doses of intranasal IRBP delivery is not related to total antigen dose.

As our previous experiments showed one dose but not three consecutive doses of 40 µg protected against the development of target organ destruction in EAU. Experiments were then designed to determine whether protection was due to either the total amount of antigen administered or to the timing of antigen delivery. Five groups of mice (n=6 in each group) were tolerised with either two or three consecutive doses of IRBP or a single delivery of antigen. All test groups received a total dose of 45 µg IRBP/mouse or equivalent volume of PBS in controls. As shown in Figure 3, which
confirmed our previous experiments, animals that received a single intranasal antigen dose displayed greatest disease suppression (incidence 5/6, grade 2.5), with fewest signs of inflammatory cell infiltrate or target organ destruction (ROS). Animals receiving 45 µg of IRBP intranasally over 3 days were not protected (incidence 6/6, EAU grade 6.8).

**INTRANASAL IRBP ADMINISTRATION INHIBITS BOTH THE INFLAMMATORY CELLS INFILTRATE AND TARGET TISSUE DAMAGE DURING EAU**

Intranasal administration of retinal antigen using either the long term/low dose or the short term/high dose regimen significantly suppressed target organ (ROS) damage. Representative histological appearances shown in Figure 4 document both significant reduction in leucocytic infiltration and structural retinal damage during IRBP induced EAU in tolerised animals. Mice pretreated with PBS developed severe EAU with marked damage to target organ ROS, and leucocytic infiltration including retinal vasculitis and perivasculitis, inflammatory cell infiltration within vitreous, and all layers of retina and choroid (Fig 4c). Frequently, the ROS layer was completely destroyed and heavily infiltrated with CD45+ leucocytes (Fig 4f), haemorrhage, and exudate.

In comparison, animals that had received multiple low tolerogenic doses of IRBP intranasally, showed reduced infiltrating leucocyte numbers concurrent with minimal ROS loss (Fig 4a and b). Immunohistochemical staining with CD45 in the “short term” tolerised mice showed a similar pattern of infiltrating cell distribution in vitreous, inner retinal layers but not in the target organ. In these animals, the ROS layer remained intact (Fig 4d and e).

**Discussion**

Oral and nasal mucosal administration of antigen have been identified as a useful means to induce antigen specific immunological tolerance. However, tolerance induction is related to the route of antigen administration (oral, nasal, or parenteral), type of antigen (whole protein, peptide, or altered peptide), and timing with regard to disease onset. The possibility of enhancing rather than inhibiting immunity is also raised depending on the conditions prevailing while antigen is administered. The quantity of the administered antigen usually influences the tolerogenic effect, although no criterion of dose dependent effect of mucosal tolerance so far has been established in any animal or human trials. Our results show that intranasal inoculation with IRBP had different effects on murine...
IRBP induced EAU according to both dose and frequency of administration. Maximal inhibition of both the incidence and severity of EAU in IRBP induced B10RIII mice was noticed in those mice pretreated with multiple small doses (total 10 µg) of IRBP. This is in agreement with our previous data from the rat EAU model that showed suppression of EAU can be achieved by administering multiple low doses of retinal extract, S-Ag, or IRBP via the nasorespiratory tract. However, Tsitoura et al reported that low doses such as 0.1 µg administered intranasally over 3 days failed to downregulate T cell responsiveness. The importance of dose and dosing regimen is also recognised in oral tolerance: feeding the antigen three times did not protect the mice against EAU while multiple feedings (five times) protected against disease induction. These results may indicate that in a low dose pretreatment regimen (10 days in our experiment), the dosage level is critical to achieve protection. The results of this and other studies suggest that long term/low dose regimen of intranasal administration of autoantigen is potentially a safe and effective route for antigen based immunotherapy for autoimmune disease.

With respect to manipulating dose, we observed that a single or at most two high doses of antigen were protective. This is in agreement with a study in a spontaneous insulin dependent diabetes murine model which showed that a single intranasal administration of 50 µg GAD65 peptides induces a Th2 cell response that inhibited the spontaneous development of autoreactive Th1 responses and the progression of β cell autoimmunity in NOD mice. However, our results also showed that multiple high doses (three doses) were ineffective in protecting against EAU. Moreover, it was the single administration of 45 µg, but not a total amount of 45 µg (15 µg per day) over 3 days that achieved protection in mice. One interpretation, therefore, is that not only the dose, but also the frequency of administration is critical to nasal mucosal tolerance induction. The therapeutic window is therefore small when using higher doses of antigen and may thus be a less successful approach when translated into clinical use.

The mechanisms by which mucosal tolerance is mediated are only partly understood. It is suggested that different mechanisms operate at different doses both in oral and nasal tolerance. Low dose tolerance is mediated by active suppression, while high doses of antigen tend to induce anergy or clonal deletion. Recently, controversial results regarding the function of Th3 T cells in mucosal tolerance have been reported. Baggi et al suggest that Th3 cells were not involved in oral tolerance induction, although this is in disagreement with other reports that show an induction of antigen specific TGF-β producing T cells are involved in disease suppression. There is further evidence from clinical observations in patients with multiple sclerosis that antigen specific TGF-β1 secreting T cells represent a distinct lineage of T cells that localise to the target organ and then suppress inflammation in the local microenvironment.

In the present study, we attempted to use flow cytometry to detect the changes of activation markers on CD4 and CD8 T cells in the draining lymph nodes after adoptive co-transfer of splenic T cells from GAD64 peptide treated mice protects recipient NOD-scid/scid mice from IDDM. The two studies, by using different dose regimens for nasal tolerance in different autoimmune disease models, both showed the generation of Th2 cells and disease protection following transfer of splenocytes. One theory, therefore, is that multiple mechanisms are operative during high dose/short term and long term/low dose regimens so as to prevent the host from generating proinflammatory immunity to ingested antigen.

In conclusion, our results suggest that the effect of intranasal administration of autoantigens against autoimmune diseases is both dose and frequency dependent, and that successful tolerance induction is dependent upon route, antigen, species, and strain. These findings have important implications for the therapeutic applications of nasal tolerance in the clinic.

The authors would like to acknowledge funding from WH Ross Foundation for the Prevention of Blindness, Saving sight in Grampian Campaign, and the Development Trust of Aberdeen University.

Jiang, Taylor, Duncan, et al.

4 Chan CC, Caspi, RR, Ni M, et al. Pathology of experimen-

5 Xiao BB, Link H. Muscular tolerance: a two-edged sword to
prevent and treat autoimmune diseases. Clin Immunol Im-

6 Higgins PJ, Winer HL. Suppression of experimental
autoimmune encephalomyelitis by oral administration of
myelin basic protein and its fragment. J Immunol 1988;140:
460–5.

7 Wang ZY, Qian J, Link H. Suppression of experimen-
tal autoimmune myasthenia gravis by oral administra-

8 Ma CG, Zhang GX, Xiao BG, et al. Suppression of exper-
imental autoimmune myasthenia gravis by nasal adminis-
tration of acetylcholine receptor. J Neuroimmunol 1995;58:
175–82.

9 Zhang ZJ, Lee CSY, Lider O, et al. Suppression of adjuvant
arthritis in Lewis rats by oral administration of type II col-

10 Daniel D, Wegmann DR. Protection of nonobese diabetic
mice from house dust mite responses by intranasally admin-
istered peptide: orally tolerised mice display enhanced sus-
ceptibility to house dust mite feeding protocols. J Autoimmun

11 Nussenzveig RB, Caspi RR, Mahdi H, et al. Inhibition of S-Ag
induced experimental autoimmune uveoretinitis by oral
administration of tolerance with S-Ag. J Immunol 1999;162:
1689–95.

12 Dick AD, Kreutzer B, Lalotou B, et al. Effects of mycophene-
tol on oral tolerance to myelin basic protein induction. J Eur

in a murine model of relapsing experimental autoimmune
uveoretinitis (EAU): induction of protective tolerance in

exposure to protein antigens induces immunological toler-
ance mediated by functionally disabled CD4+ T cells. J Immu-
nol 1999;163:2592–600.

administration of myelin basic protein and its fragment.

treatment potentiates induction of oral tolerance in
nonobese diabetic mice: a role for IL-12. J Immunol 1999;163:
2348–57.

17 McMenamin C, Primm C, McKersey M, et al. Oral toler-
ization of Th1 responses and prevents murine insulin-

18 Holt PG, Sly PD. Gammadelta T cells provide a breath of

19 Gregersen DS, O'Brian WC, Donoso LA. Oral toler-
ance in experimental autoimmune uveoretinitis: distinct
mechanisms of resistance are induced by low zone versus high

20 Garside P, Steel M, Liew FY, et al. CD4+ but not CD8+ T
cells are required for the induction of oral tolerance. J Immu-

21 Rizzo LV, Miller-Rivero NE, Chan CC, et al. Interleukin-2
treatment potentiates induction of oral tolerance in a

22 Mckenna C, Primc C, McKersey M, et al. Regulation of IgE
responses to inhaled antigens in mice by antigen-
specific gamma delta T cells. Science 1993;265:1869–70.

23 Holt PG, Sly PD. Gammadelta T cells provide a breath of

24 Herbelin AH, Gombert JM, Lepault F, et al. Oral admi-
istration of单价谷氨酰胺-binding protein results in 'active toler-

25 Hoyne GF, Askonas BA, Hezel C, et al. Regulation of house
dust mite responses by intranasally administered peptide:
transient activation of CD4+ T cells precedes the develop-

26 Garside P, Steel M, Worthy EA, et al. Lymphocytes from orally
 tolerised mice display enhanced susceptibility to
death by apoptosis when cultured in the absence of antigen

27 Rizzo LV, Morawetz RA, Miller-Rivero NE, et al. IL-4 and
IL-10 are both required for the induction of oral tolerance.
Total dose and frequency of administration critically affect success of nasal mucosal tolerance induction

Hui-Rong Jiang, Neil Taylor, Linda Duncan, Andrew D Dick and John V Forrester

*Br J Ophthalmol* 2001 85: 739-744
doi: 10.1136/bjo.85.6.739